Longlight Secures Tens of Millions RMB in Pre-A Funding to Accelerate Global Expansion of Integrated Laboratory Sample Processing Solutions

VCBeat has learned that Shenzhen Dayuan Chenguang Technology Co., Ltd. (hereinafter referred to as“Dayuan Chenguang”）Announces Completion of Tens of Millions of RMBPre-ARound of financing. ThisLun YouOldShareholderYhlo(Stock Code:688575）Lead Investor,Yanghe InvestmentCo-investment. The funds raised will be used forGlobal Market Development,New Product DevelopmentandCapacity Expansion, forDayuan Chenguang Enhances Product Line and PromotesInternationalization Strategy ProvisionRobustCoverage.

Longlight focuses on providing integrated solutions for diagnostic research and molecular biology to meet the needs of future laboratories. The company is composed of university professors, overseas technical teams, and senior experts with decades of experience in the biotechnology market. With extensive industry expertise in structural biology, biochemistry, automatic control, and organic chemistry, Longlight has assembled a multidisciplinary team spanning instrument automation, theoretical physics, and biochemistry.

The company is dedicated to advancing fundamental scientific research, focusing on two core product segments: biological sample processing and protein science. It provides international-quality products and services to customers engaged in biopharmaceutical research, translational medicine, and basic scientific research. The company has pioneered the launch of China’s first focused ultrasonic sample processing system. This system ensures an isothermal, non-contact, and standardized sample processing workflow, serving as the gold standard for DNA fragmentation in next-generation sequencing (NGS) library preparation, and has been applied to single-cell proteomics sample extraction and preparation. Currently, the focused ultrasonic sample processing system has achieved a significant market share. The company continues to develop a diverse range of innovative life science reagents and service products, safeguarding customers’ R&D and production processes.

Life science workflows are intricate and complex, with high-quality sample extraction serving merely as the first step toward success. To support downstream processes in biological laboratories, the company has sequentially launched products and services including uniform magnetic field separation systems, ultra-fast macromolecule separation technology, cryo-electron microscopy (cryo-EM) structure analysis services, and chemical cross-linking mass spectrometry (XL-MS) services, thereby providing comprehensive solutions for global life science research.

Over the past two years, Dayuan Chenguang has actively expanded into overseas markets, with its products exported to Europe, Japan, the Americas, and other international regions. With the infusion of capital from this financing round, Dayuan Chenguang will further intensify its R&D efforts to expand its product pipeline, create new growth engines, and tap into broader global markets.

Kang Yan, Founder of Dayuan Chenguangstated, “We are delighted to have secured the recognition and renewed support of our existing shareholders. This not only affirms our past achievements but also demonstrates confidence in our future growth potential. The funds will be primarily allocated to expanding our R&D team, enriching our product pipeline, and optimizing the customer service experience. This year, we plan to intensify our promotional efforts in international markets, particularly in Europe, Japan, and the United States, to better meet the global demand for medical research. We remain committed to the research and development of innovative technologies and their market application, contributing greater strength to life sciences research worldwide.”

Qian Chungeng, Director and Deputy General Manager of Yhlo Groupstated: “We are highly confident in the long-term growth prospects of Dayuan Chenguang. The company has demonstrated strong technical capabilities and market competitiveness in biological sample preparation, proteomics, and nucleic acid research. We believe that, with the support of this new round of financing, Dayuan Chenguang will achieve greater breakthroughs on the international stage, particularly in developed markets represented by Europe, Japan, and the United States.”

Fu Chao, Vice President of Yanghe Investmentstated: “Since our initial investment in 2021, Dayuan Chenguang has achieved rapid performance growth. Its first product, the focused ultrasound sample processing system, has been progressively adopted and recognized by renowned end-users and representative industry enterprises in China, securing a significant market share. The company has also made substantial progress in the research and development of new products and the expansion into overseas markets. We are confident in Dayuan Chenguang’s long-term development prospects and hope that this round of investment will help the company achieve better and faster growth, enabling it to soon become a leading enterprise in the sample processing field, with a foothold in both domestic and international markets and a diversified product pipeline.”

Shenzhen Yahuilong Biological Technology Co., Ltd. was established in 2008 and is a well-known company listed on the STAR Market (Stock Code: 688575). As an innovative enterprise in the field of in vitro diagnostics (IVD), the company boasts domestically leading technology and focuses on providing comprehensive solutions for clinical laboratories. Its core business involves the research and development, production, and sales of IVD instruments and supporting reagents, primarily based on chemiluminescence immunoassay (CLIA) technology. Upholding its mission of “Dedication to Life and Health, Striving to Benefit Humanity through Technology,” the company remains committed to excellence, continuously delivering superior products and services to advance global health.

Founded in 2013, Yanghe Investment is a China-based industrial investment firm specializing in niche healthcare sectors. It focuses primarily on medical technologies, innovative medical devices, and healthcare services, with its portfolio concentrated in early- to mid-stage companies. Committed to long-term value creation, the firm identifies investment opportunities through in-depth sector research and empowers its portfolio companies, achieving its own growth alongside that of its investments. To date, Yanghe Investment has invested in more than 30 high-quality enterprises, including Vishee Medical, Libo Pharmaceutical, Kanglu Biotechnology, Mingkang Medical, Genenode Biotechnology, Respree, Ruitong Biopharma, and Bosheng Medical.